Inhibitors of the pd-1/pd-l1 protein/protein interaction
US-2019016681-A1 · Jan 17, 2019 · US
US12448359B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12448359-B2 |
| Application number | US-202117908530-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 5, 2021 |
| Priority date | Mar 11, 2020 |
| Publication date | Oct 21, 2025 |
| Grant date | Oct 21, 2025 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention generally relates to new compounds for therapeutic uses. In particular, the disclosed series compounds with immunomodulatory activities are useful for treatment of dysfunctions of the immune system and various cancers. Pharmaceutical composition matters and methods for treating a patient with an immune disease and/or a cancer by administering therapeutically effective amounts of such compound alone or together with other therapeutics are within the scope of this disclosure.
Opening claim text (preview).
The invention claimed is: 1. A compound having the formula (I): or a pharmaceutically acceptable salt thereof, wherein Ar 1 is 2,3-dihydrobenzo [b] [1,4]-dioxinyl; R 1 and R 2 are each, independently, alkyloxy; R 3 is alkyl; and Q is 2. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are each methoxyl. 3. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is CH 3 . 4. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is: 5. A pharmaceutical composition comprising one or more compounds of claim 1 , or a pharmaceutically acceptable salt thereof, together with one or more diluents, excipients or carriers. 6. A method for treating a cancer patient, which method comprises administering a therapeutically effective amount of one or more compounds of claim 1 , or a pharmaceutical composition comprising same and one or more carriers, diluents, or excipients, to the cancer patient. 7. The method according to claim 6 , wherein said cancer is castration-resistant prostate cancer.
Organoboranes and organoborohydrides · CPC title
containing three or more hetero rings · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
containing three or more hetero rings · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.